Several patient groups are lambasting the U.S. Trade Representative over its latest annual list that identifies and ranks countries based on a willingness to protect intellectual property, calling it “shameful” and “outrageous.”

Known as the Special 301 Report, the yearly exercise is of great concern to drug makers, which regularly argue that some countries fail to sufficiently protect and enforce patent rights. By the same token, the list is also closely tracked by patient advocacy groups for clues into trade and patent policies that governments may adopt concerning access to medicines.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe the quote is interesting – “America needs to fight back, which is why we are encouraged the Trump Administration is taking on foreign governments,” – since one of the companies being defended seems to be Novartis. (I may be confused but I had the idea they were Swiss?)
    And “fighting back” against as staunch an ally as Canad is …. “bemusing” to say the least.

Your daily dose of news in health and medicine

Privacy Policy